{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:08:10Z","timestamp":1774314490236,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jfo.2026.104808","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:34:15Z","timestamp":1772192055000},"page":"104808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Retinal toxicity following SBP-101 combined with gemcitabine and nab-paclitaxel chemotherapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Z.","family":"Driouich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.G.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.104808_bib0085","doi-asserted-by":"crossref","first-page":"818","DOI":"10.25122\/jml-2023-0041","article-title":"Ocular adverse effects of anti-cancer chemotherapy","volume":"16","author":"Stoicescu","year":"2023","journal-title":"J Med Life"},{"key":"10.1016\/j.jfo.2026.104808_bib0090","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.survophthal.2005.11.001","article-title":"Update on ocular complications of systemic cancer chemotherapy","volume":"51","author":"Schmid","year":"2006","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104808_bib0095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/ICB.0000000000000471","article-title":"Gemcitabine-induced retinopathy","volume":"12","author":"Kovach","year":"2018","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.jfo.2026.104808_bib0100","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/24741264231157140","article-title":"Chemotherapy-induced retinopathy in a diabetic and hypertensive patient with stage 4 metastatic pancreatic adenocarcinoma","volume":"7","author":"Brummer","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.jfo.2026.104808_bib0105","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3928\/23258160-20220316-01","article-title":"Gemcitabine-associated retinopathy with bilateral exudative retinal detachment and Elschnig's spots","volume":"53","author":"Loscalzo","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2026.104808_bib0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s10792-017-0698-9","article-title":"Bilateral macular infarction after gemcitabine and carboplatin chemotherapy","volume":"38","author":"Behera","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104808_bib0115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/crst.crst_18_23","article-title":"Irreversible bilateral optic neuropathy from gemcitabine-oxaliplatin combination chemotherapy: a case report","volume":"6","author":"Chatterjee","year":"2023","journal-title":"Cancer Res Stat Treat"},{"key":"10.1016\/j.jfo.2026.104808_bib0120","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3928\/23258160-20240227-01","article-title":"Case report: macula structural and functional assessment in nab-paclitaxel\u2013related cystoid macular edema","volume":"55","author":"Kwok","year":"2024","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jfo.2026.104808_bib0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1089\/jop.2011.0178","article-title":"Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): clinical experience with intravitreal bevacizumab","volume":"29","author":"Rahman","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jfo.2026.104808_bib0130","doi-asserted-by":"crossref","first-page":"100653","DOI":"10.1016\/j.ajoc.2020.100653","article-title":"Dexamethasone intravitreal implant in cystoid macular edema secondary to paclitaxel therapy","volume":"18","author":"Burgos-Blasco","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.jfo.2026.104808_bib0135","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/ICB.0000000000000143","article-title":"Cystoid macular edema and macular pigmentation associated with nab-paclitaxel therapy","volume":"9","author":"Haider","year":"2015","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.jfo.2026.104808_bib0140","first-page":"449","article-title":"A case of a corneal disorder after breast cancer treatment with nab-paclitaxel","volume":"120","author":"Hosotani","year":"2016","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.jfo.2026.104808_bib0145","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.2022.40.4_suppl.575","article-title":"Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma","volume":"40","author":"Singhal","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jfo.2026.104808_bib0150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.molmed.2024.03.008","article-title":"Exploiting pancreatic cancer metabolism: challenges and opportunities","volume":"30","author":"De Santis","year":"2024","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jfo.2026.104808_bib0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14737140.2024.2357802","article-title":"The trend toward more target therapy in pancreatic ductal adenocarcinoma","volume":"24","author":"Deiana","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jfo.2026.104808_bib0160","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2021.39.15_suppl.4127","article-title":"SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma","volume":"39","author":"Singhal","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551226000343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T17:42:28Z","timestamp":1774287748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551226000343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0181551226000343"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104808","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal toxicity following SBP-101 combined with gemcitabine and nab-paclitaxel chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104808"}}